Publications by authors named "Julijana Asllani"
Article Synopsis
- The study looked at how safe allergen immunotherapy (AIT) is in real-life situations by keeping track of any negative reactions people had.
- They found that out of 1,545 adults getting AIT for allergies, only a small number (about 7.4%) experienced adverse events, and serious reactions were very rare.
- Having asthma and using a certain type of AIT called subcutaneous immunotherapy (SCIT) put some people at a higher risk of side effects, while using modified allergens seemed to help reduce the risk.
Article Synopsis
- - The traditional healthcare approach often overlooks patients' personal experiences and strengths, focusing mainly on disease treatment. Person-centered care aims to align medical decisions with individual values and preferences, particularly for those with chronic conditions.
- - This paper seeks to enhance care for rhinitis and asthma by developing digital care pathways and incorporating real-world evidence to create a more patient-centered approach.
- - Key components of the review include advancements in mHealth, the integration of artificial intelligence, a novel classification system for airway diseases, and proposals for the ARIA 2024 guidelines, all targeting a sustainable and applicable healthcare model.
Background: Although it has been shown that allergen immunotherapy (AIT) is well-tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed.
Methods: The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved.